Celgene acquires autoimmune startup Delinia for $775M
On Thursday, Summit, New Jersey-based Celgene announced plans to acquire Delinia for an upfront $300 million and an additional $475 million in milestone-based payments. Delinia has a preclinical program that could be applied to a range of autoimmune diseases.